Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT04265378 Completed - Clinical trials for Mild Cognitive Impairment

Cognitive Training and Brain Stimulation in Prodromal Alzheimer's Disease

AD-Stim
Start date: May 1, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to investigate whether a tDCS-accompanied intensive cognitive training of working memory leads to performance improvement in individuals with prodromal Alzheimer's disease.

NCT ID: NCT04263519 Withdrawn - Alzheimer Disease Clinical Trials

A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

A Pilot open labeled study of Tacrolimus in Alzheimer's Disease.

NCT ID: NCT04262674 Active, not recruiting - Clinical trials for Mild Cognitive Impairment

Non-invasive, Wearable Multi-parameter System for the Early Prediction of Cognitive Decline and Dementia in Older Adults

Start date: September 23, 2019
Phase: N/A
Study type: Interventional

This project develops an innovative screening system and prediction model to detect preclinical symptoms of cognitive impairment and predict the potential development of mild cognitive impairments and dementia in older adults. The earliest possible detection of preclinical symptoms is prerequisite to improve the efficacy of subsequent preventative non-pharmacological, life-style and exercise related, personalized treatment interventions.

NCT ID: NCT04262206 Recruiting - Clinical trials for Cardiovascular Diseases

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

PREVENTABLE
Start date: September 1, 2020
Phase: Phase 4
Study type: Interventional

PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.

NCT ID: NCT04259047 Recruiting - Diabetes Clinical Trials

Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans With Diabetes and Mild Cognitive Impairment: A Randomized Clinical Trial

DREAM
Start date: October 25, 2021
Phase: Phase 2
Study type: Interventional

This double-masked, 2-year, single-site, phase II RCT will test the efficacy of DREAM (Diabetes Regulation for Eye Sight and Memory to prevent cognitive decline in African Americans (AAs) with amnestic multiple domain mild cognitive impairment (MCI) and poorly controlled diabetes (i.e., hemoglobin A1c [HbA1c] level ≥ 7.5%). Participants will be randomized to DREAM [11 home-based treatment sessions with a community health worker (CHW), and 4 telehealth visits with a Diabetes Nurse Educator over 2 years] or Enhanced Usual Care (EUC), which is usual care enhanced with home-based diabetes education. The primary outcome is decline in verbal memory over 2 years. Follow-up data will be collected at 6, 12, 18, and 24 months. In addition, participants will have ophthalmology assessments (at Wills) at baseline, 12 and 24 months to determine whether retinal Vessel Area Density, and/or Retinal Nerve Fiber Layer thickness mediate DREAM's treatment effect.

NCT ID: NCT04255225 Completed - Breast Cancer Clinical Trials

Making Activity Time for Cognitive Health

MATCH
Start date: September 2016
Phase: N/A
Study type: Interventional

Approximately 75% of cancer survivors experience some degree of cognitive deficit throughout their cancer experience, with upwards of one third of breast cancer survivors reporting impairments up to a decade after treatment. Chemotherapy and adjuvant therapy to remove cancerous tissue can result in deficits in attention, speed of processing, memory, and quality of life. Physical activity has been associated with a number of health benefits for breast cancer survivors including improvements in cognitive function. The investigators recently reported on the beneficial effects of acute exercise, or single sessions of physical activity, on processing speed and spatial working memory in breast cancer survivors, suggesting that acute bouts of physical activity may mitigate select domains of CRCI. Specifically, survivors in this study demonstrated faster processing speed, and trended towards faster and more accurate spatial working memory, after thirty minutes of moderate-intensity walking compared to seated rest. But half an hour of walking may be challenging to certain subgroups of survivors, particularly those who are deconditioned or with significant barriers to longer walks. With a renewed focus on un-bouted physical activity and avoiding inactivity during survivorship, it is important to better understand the dose or volume of exercise responsible for providing breast cancer survivors with the greatest cognitive benefits. The investigators examined the effects of varying durations of exercise (e.g., 10, 20 and 30 minutes) on cognitive function in breast cancer survivors to identify the optimal length of acute exercise. Findings from this study will inform new guidelines for acute exercise after cancer.

NCT ID: NCT04253587 Completed - Clinical trials for Mild Cognitive Impairment

Wayfinding Intervention in High-Fidelity Long-Term Memory

LABYR
Start date: October 1, 2019
Phase: N/A
Study type: Interventional

Therapeutic treatment is yet available for declining memory, which is an impairment affecting the quality of life for many older adults and patients with cognitive impairment. Cognitive training with an immersive video game promises to drive hippocampal-cortical plasticity and associated gains that can restore memory capability or provide therapeutic treatment for memory deficits.

NCT ID: NCT04251624 Recruiting - Clinical trials for Post Traumatic Stress Disorder

Investigating the Use of Goal Management Therapy in Improving Cognitive Functioning in Public Safety Personnel With PTSD

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

This study examines the efficacy of Goal Management Therapy (GMT) - a well-established cognitive remediation strategy aimed at improving goal-directed behaviors that are dependent on basic cognitive processes and on executive functioning - among public safety personnel with post-traumatic stress disorder.

NCT ID: NCT04251130 Recruiting - Clinical trials for Mild Cognitive Impairment

Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI

Start date: March 11, 2020
Phase:
Study type: Observational

The investigators will conduct a tau PET scan in cognitively normal older adults and patients with Mild Cognitive Impairment (MCI), enrolled in the National Alzheimer's Coordinating Center (NACC) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).

NCT ID: NCT04250935 Completed - Clinical trials for Cognitive Dysfunction

Brain-Induced Neurotrophic Factor Levels in Patients Undergoing Coronary Artery Bypass Surgery

Start date: January 15, 2020
Phase:
Study type: Observational

In patients undergoing coronary artery bypass surgery, the relationship between neurocognitive changes seen in the early period and brain-induced neurotrophic factor serum levels will be investigated.